Announcements

On 19 November 2024, Clarivate^TM released its 2024 Highly Cited Researchers^TM list, for which 6636 researchers from universities, research institutes, and commercial organizations around the world were selected. We are pleased to announce that ten Editorial Board Members of the Journal of Clinical Medicine (JCM, ISSN: 2077-0383) have been selected for the list, recognized for their high-quality scientific research and outstanding contributions to their fields of expertise. The Editorial Office of the Journal of Clinical Medicine would like to congratulate all the selected Editorial Board Members and look forward to continuing our close and productive collaboration.

The following is a list of the ten Editorial Board Members who were named as highly cited researchers in 2024:

In addition, 685 Editorial Board Members of MDPI journals were honored, and we wish to congratulate them on their achievement and contributions to advancing knowledge in their respective fields. To access more information on the 685 Editorial Board Members, please visit the following link: https://www.mdpi.com/about/announcements/9911.

For more information about the JCM Editorial Board, please visit the following link: https://www.mdpi.com/journal/jcm/editors.

We are delighted to share some highly cited papers on brain injury that were published in the Journal of Clinical Medicine (JCM, ISSN: 2077-0383) in 2023. In addition, some Special Issues on the topic of brain injury are currently open for submission. The following is a list of articles and Special Issues that we believe will interest you.

1. “Transcranial Direct Current Stimulation for Chronic Stroke: Is Neuroimaging the Answer to the Next Leap Forward?”
by Claudia A. Salazar, Wuwei Feng, Leonardo Bonilha, Steven Kautz, Jens H. Jensen, Mark S. George and Nathan C. Rowland
J. Clin. Med. 2023, 12(7), 2601; https://doi.org/10.3390/jcm12072601
Available online: https://www.mdpi.com/2077-0383/12/7/2601

2. “Neuroworsening in the Emergency Department Is a Predictor of Traumatic Brain Injury Intervention and Outcome: A TRACK-TBI Pilot Study”
by John K. Yue, Nishanth Krishnan, John H. Kanter, Hansen Deng, David O. Okonkwo, Ava M. Puccio, Debbie Y. Madhok, Patrick J. Belton, Britta E. Lindquist, Gabriela G. Satris et al.
J. Clin. Med. 2023, 12(5), 2024; https://doi.org/10.3390/jcm12052024
Available online: https://www.mdpi.com/2077-0383/12/5/2024

3. “The Putative Role of Neuroinflammation in the Interaction between Traumatic Brain Injuries, Sleep, Pain and Other Neuropsychiatric Outcomes: A State-of-the-Art Review”
by Alberto Herrero Babiloni, Andrée-Ann Baril, Camille Charlebois-Plante, Marianne Jodoin, Erlan Sanchez, Liesbet De Baets, Caroline Arbour, Gilles J. Lavigne, Nadia Gosselin and Louis De Beaumont
J. Clin. Med. 2023, 12(5), 1793; https://doi.org/10.3390/jcm12051793
Available online: https://www.mdpi.com/2077-0383/12/5/1793

4. “Reference Values of the Quality of Life after Brain Injury (QOLIBRI) from a General Population Sample in Italy”
by Ugne Krenz, Sven Greving, Marina Zeldovich, Juanita Haagsma, Suzanne Polinder, Nicole von Steinbüchel and on behalf of the CENTER-TBI Participants and Investigators
J. Clin. Med. 2023, 12(2), 491; https://doi.org/10.3390/jcm12020491
Available online: https://www.mdpi.com/2077-0383/12/2/491

5. “Investigating the Effectiveness of a Family Intervention after Acquired Brain or Spinal Cord Injury: A Randomized Controlled Trial”
by Pernille Langer Soendergaard, Juan Carlos Arango-Lasprilla, Mia Moth Wolffbrandt, Frederik Lehman Dornonville de la Cour, Fin Biering-Sørensen and Anne Norup
J. Clin. Med. 2023, 12(9), 3214; https://doi.org/10.3390/jcm12093214
Available online: https://www.mdpi.com/2077-0383/12/9/3214

6. “Advances in Stroke Neurorehabilitation”
by Muhammed Enes Gunduz, Bilal Bucak and Zafer Keser
J. Clin. Med. 2023, 12(21), 6734; https://doi.org/10.3390/jcm12216734
Available online: https://www.mdpi.com/2077-0383/12/21/6734

7. “Catheter Ablation for Tachyarrhythmias in Left Ventricular Assist Device Recipients: Clinical Significance and Technical Tips”
by Kati Hayes, Sam Harding, Kirsten Buckley, Bronagh Blackwood and Jos M. Latour
J. Clin. Med. 2023, 12(13), 4197; https://doi.org/10.3390/jcm12134197
Available online: https://www.mdpi.com/2077-0383/12/13/4197

8. “Evolving Clinical–Translational Investigations of Cerebroprotection in Ischemic Stroke”
by Yinghui Li, Laurel E. Schappell, Claire Polizu, James DiPersio, Stella E. Tsirka, Marc W. Halterman and Neil A. Nadkarni
J. Clin. Med. 2023, 12(21), 6715; https://doi.org/10.3390/jcm12216715
Available online: https://www.mdpi.com/2077-0383/12/21/6715

9. “Current and Emerging Endovascular and Neurocritical Care Management Strategies in Large-Core Ischemic Stroke”
by Qing He, Yixia Lin, Ye Zhu, Lang Gao, Mengmeng Ji, Li Zhang, Mingxing Xie and Yuman Li
J. Clin. Med. 2023, 12(20), 6641; https://doi.org/10.3390/jcm12206641
Available online: https://www.mdpi.com/2077-0383/12/20/6641

10. “Acute Haemostatic Depletion and Failure in Patients with Traumatic Brain Injury (TBI): Pathophysiological and Clinical Considerations”
by Fabian Kockelmann and Marc Maegele
J. Clin. Med. 2023, 12(8), 2809; https://doi.org/10.3390/jcm12082809
Available online: https://www.mdpi.com/2077-0383/12/8/2809

11. “Challenges of the Effectiveness of Traumatic Brain Injuries Biomarkers in the Sports-Related Context”
by Rossella Tomaiuolo, Martina Zibetti, Chiara Di Resta and Giuseppe Banfi
J. Clin. Med. 2023, 12(7), 2563; https://doi.org/10.3390/jcm12072563
Available online: https://www.mdpi.com/2077-0383/12/7/2563

12. “Update on Pediatric Mild Traumatic Brain Injury in Rural and Underserved Regions: A Global Perspective”
by John K. Yue, Nishanth Krishnan, John P. Andrews, Alexa M. Semonche, Hansen Deng, Alexander A. Aabedi, Albert S. Wang, David J. Caldwell, Christine Park, Melessa Hirschhorn et al.
J. Clin. Med. 2023, 12(9), 3309; https://doi.org/10.3390/jcm12093309
Available online: https://www.mdpi.com/2077-0383/12/9/3309

13. “Multi-Mechanistic Approaches to the Treatment of Traumatic Brain Injury: A Review”
by Daniel G. Lynch, Raj K. Narayan and Chunyan Li
J. Clin. Med. 2023, 12(6), 2179; https://doi.org/10.3390/jcm12062179
Available online: https://www.mdpi.com/2077-0383/12/6/2179

14. “Quality of Life after Brain Injury in Children and Adolescents (QOLIBRI-KID/ADO)—The First Disease-Specific Self-Report Questionnaire after Traumatic Brain Injury”
by Nicole Von Steinbuechel, Marina Zeldovich, Sven Greving, Laiene Olabarrieta-Landa, Ugne Krenz, Dagmar Timmermann, Inga K. Koerte, Michaela Veronika Bonfert, Steffen Berweck, Matthias Kieslich et al.
J. Clin. Med. 2023, 12(15), 4898; https://doi.org/10.3390/jcm12154898
Available online: https://www.mdpi.com/2077-0383/12/15/4898

15. “Impact of Sociodemographic, Premorbid, and Injury-Related Factors on Patient-Reported Outcome Trajectories after Traumatic Brain Injury (TBI)”
by Nicole von Steinbuechel, Stefanie Hahm, Holger Muehlan, Juan Carlos Arango-Lasprilla, Fabian Bockhop, Amra Covic, Silke Schmidt, Ewout W. Steyerberg, Andrew I. R. Maas, David Menon et al.
J. Clin. Med. 2023, 12(6), 2246; https://doi.org/10.3390/jcm12062246
Available online: https://www.mdpi.com/2077-0383/12/6/2246

You are invited to view and submit relevant papers to the Journal of Clinical Medicine at the following link: https://www.mdpi.com/journal/jcm.

JCM Editorial Office

More than 100 German universities and research institutions have entered into a national agreement with MDPI. The publication agreement negotiated by ZB MED comes into effect on 1 January 2025 and is valid until the end of 2026. Joining the consortium is still possible until the beginning of 2025. We are delighted by the high level of interest this agreement has already garnered, reflecting the strong demand for accessible and cost-effective open access publishing solutions among German research institutions.

This new cooperation aims to make scientific gold open access publishing more affordable and less administratively burdensome for researchers in Germany. The agreement includes substantial discounts on article processing charges (APCs) for corresponding authors from participating institutions. It offers flexible payment options, including centralized invoicing or individual payment of fees by researchers or their institutions. Additionally, the agreement features a flat-fee model that enables institutions to precisely plan expenses and optimize their library budgets.

"MDPI can look back on over a decade of successful partnerships with German research institutions," says Peter Roth, MDPI Head of Publishing. "The new agreement marks another milestone in the long-standing co-operation between MDPI and the German scientific community. It emphasizes our commitment to developing up-to-date and inventive solutions for the diverse needs of scientific institutions to promote open research for the benefit of researchers."

Petra Labriga, Head of Strategic License Management at ZB MED, highlighted the agreement's significance: "As one of the world's leading Gold OA publishers, MDPI plays a central role in the German publishing landscape. We are particularly pleased that we were able to achieve considerable potential cost savings for scientific institutions and their authors at a national level through our negotiations."

The partnership reflects a common goal of advancing the idea of open access and supporting researchers in making their scientific excellence internationally visible.

"We would like to thank the ZB MED consortium team for their excellent collaboration," added Adrian Stefan Zamfir, MDPI Institutional Partnership Manager for the DACH region. "We are delighted that this agreement will give even more researchers in Germany access to our tried-and-tested and reliable publication platform."

Franziska Fischer (right), Commercial Director at ZB MED, an Peter Roth (left), Head of Publishing at MDPI, celebrate the signing of the new national open access agreement between MDPI and the ZB MED Consortium.

More Information

• Conditions and participation opportunities (German): Link
• Frequently asked questions (German): Link

Contact

• ZB MED: Team Konsortiallizenzen (konsortiallizenzen@zbmed.de) - Website
  MDPI: Adrian Stefan Zamfir, Institutional Partnership Manager (zamfir@mdpi.com)
  
  

About ZB MED

ZB MED - Information Centre for Life Sciences is an infrastructure and research centre for life science information and data. Its aim is to support and strengthen research for people and the environment: from medicine to biodiversity and environmental protection.

The work of ZB MED is orientated towards the strategic guidelines:

• Research + Networking: We conduct research together with the regionally, nationally, European and globally networked research community.
• Data science: We enable data analyses and generate new knowledge through research.
• Access to information: We provide sustainable access to information, literature and data as a central information infrastructure.
• Open + FAIR: We promote open and reproducible science in line with open science and FAIR principles.
• Knowledge and skills transfer: We actively impart knowledge, competences and skills.

More information at www.zbmed.de.

About MDPI

Headquartered in Basel, Switzerland, MDPI is one of the world's leading open access publishers with a current portfolio of more than 440 journals in all scientific disciplines. MDPI‘s goal is to advance open science worldwide through greater transparency, efficiency and collaboration. To date, more than 3.7 million researchers have published their results in MDPI journals. The editorial process is overseen by a large network of dedicated reviewers and editors and supported by more than 6500 MDPI employees. MDPI currently works with over 800 academic institutions and 180 scientific societies worldwide, which benefit from a wide range of MDPI services and products.

The AACR Annual Meeting is the critical driver of progress against cancer, the place where scientists, clinicians, other healthcare professionals, survivors, patients, and advocates gather to share and discuss the latest breakthroughs. From population science and prevention to cancer biology, translational and clinical studies, and survivorship as well as advocacy, the AACR Annual Meeting showcases cutting-edge cancer science and medicine.

The following MDPI journals will be represented:

• Cancers;
• IJMS;
• Healthcare;
• Cells;
• Current Oncology;
• IJERPH;
• Onco;
• Hemato;
• Diseases;
• JCM;
• Diagnostics;
• Clinics and Practice;
• JPM.

If you are attending this conference, please feel free to start an online conversation with us. Our delegates look forward to meeting you in person at booth #2819 at the conference and answering any questions that you may have. For more information about the conference, please visit the following link: https://www.aacr.org/meeting/aacr-annual-meeting-2025/.

We are pleased to announce a series of updates to our template, aimed at improving the readability and overall aesthetics of our publications. These changes have been meticulously designed to enhance the user experience and ensure consistency across all our publications. The updated template will be available for download from the Instructions for Authors page.

The following updates will be applied to articles published in the 2025 volumes, starting on 24 December 2024:

• Main text: The line spacing has been increased to improve the readability of publications;
• Header and footer: The link to the journal website will be removed, as a hyperlink has been integrated into the journal logo. Additionally, the DOI link will be moved from the left-hand side to the right-hand side, and both the header and footer will be slightly raised to achieve a better balance;
• Left information bar: The information provided here has been rearranged for better organization; the CC-BY logo will be removed;
• Font size: The font size used for the abstract, keywords, and first-level headings will be increased.

Furthermore, MDPI journals will continue to use article numbers. This approach enables us to maintain a rapid and efficient production process by being able to define pagination as soon as a paper is accepted.

We hope that the new version of the template will provide users with a better experience and make the process more convenient.

Please contact production@mdpi.com if you have any questions or suggestions.

Journal of Clinical Medicine (JCM, ISSN: 2077-0383) is an international, peer-reviewed, open access journal of clinical medicine, committed to publishing high-quality papers and promoting the development of the scientific community. We strive for a rigorous peer-review to ensure a thorough evaluation of each manuscript; this is a fundamental task for our reviewers. We are sincerely grateful to scholars who give their time to peer-review articles submitted to Journal of Clinical Medicine. Rigorous peer-review is the cornerstone of high-quality academic publishing. Our Editorial Board Members encourage young researchers to join us. We are eager to have you as a new member of our Reviewer Board.

To view reviewers’ profiles and responsibilities, please visit: https://www.mdpi.com/reviewers#_bookmark2.

Joining as a reviewer brings a host of professional advantages. It provides you with the chance to keep abreast of the most recent research trends in the field of clinical medicine, establish valuable connections within the academic community, and actively contribute to the progress of clinical medical research. For more details about the perks of being a reviewer, please visit our Reviewers' Benefits page.

To access more information about the JCM Reviewer Board, please visit the following link: https://www.mdpi.com/journal/jcm/submission_reviewers.

Name: Dr. Giuseppe Barilaro
Affiliations: 1. Department of Autoimmune Diseases, Hospital Clinic, University of Barcelona, Barcelona, Spain;
2. Department of Internal Medicine, Sant’Eugenio Hospital, Rome, Italy.

Dr. Giuseppe Barilaro presently works in the internal medicine department of the Sant’Eugenio Hospital in Rome. Besides his daily clinical activity (focusing on autoimmune diseases), he is working on several research projects started in recent years. He has so far published more than 30 articles in international indexed journals and several book chapters. The following is our interview with him.

1. How does it feel to receive this recognition for your work?
It's a big satisfaction after bringing up your own project and your research idea that comes to a result and you can publish it, and receiving recognition for it is an incredible satisfaction. Also, it increases your motivation because it's proof that developing your ideas, developing your research, and hard work always pays off. So, I cannot say enough to thank the Journal of Clinical Medicine for this recognition. That's been a very fulfilling feeling for me. It’s a wonderful feeling.

2. When and how did you access JCM? What prompted you to apply for this award? Would you like to share your experience with JCM?
Working in the field of medicine, in internal medicine, focusing especially on autoimmune diseases, I had the chance to be in contact with the Journal of Clinical Medicine several times. We also published a few papers in the Journal of Clinical Medicine with my group. So, I know the journal very well. It is a journal that I've known for a while and I usually go to check up on its webpages, and this is how I found it, on the internet pages. This is how I got the information about the prize, and I applied for it for my research.

3. Could you please give us a brief overview of your research topic and the main objectives of your Ph.D. thesis?
My Ph.D. thesis focuses on an autoimmune disease which is called antiphospholipid syndrome, and mainly on predictors of recurrence of clinical manifestations for APS (antiphospholipid syndrome).

4. Does your research field use AI technology in diagnosis and treatment? What do you think about the current advances and future opportunities of AI technology in your field?
Artificial intelligence is part of our lives and it's going to be, day by day, more and more present in our lives. It is something we cannot ignore. Focusing on my medical field, there are already several available applications that might help a clinician in establishing a diagnosis or analyzing medical reports, radiological tests, etc. The clinician’s interpretations and thinking always do make the difference, but still, when used properly, it can be a very powerful weapon in our pipeline. It significantly increases the opportunities that the clinician, doctor, and physician can have in their day-by-day practice.

5. How did you manage your time and prioritize your tasks during your Ph.D. program, and what strategies did you use to stay focused and motivated?
I started my Ph.D. right before the pandemic started, at the end of 2019. It has been hard, especially in the first part of my Ph.D., not to give up, to stay focused on my project, and its possible realization, waiting for better moments to get back to my research.

What I did was split my duties and try to focus first on collecting data and try to do it after my daily practice. When the situation improved, I spent most of the time thinking about what I could do with the data and analyzing them. I just tried to advance a little every day. I never missed the opportunity to make some progress in my day by day because it also helps in keeping yourself motivated and seeing that you can reach your goal.

6. How do you see the findings of your research impacting the field of clinical medicine and other related research areas?
As the description of my research project, the focus of my thesis was to find predictors of the recurrence of clinical manifestations in APS, a condition that affects young people with a very long life, and hopefully a long life expectancy. What I hope is that my findings will help clinicians in finding orientations to predict which patients are more likely to develop a recurrence of clinical manifestation during their lives and how to prevent that.

7. How do you plan to continue building on your research in the future, and what are your long-term career aspirations?
I’m developing, with my colleagues from Barcelona and others from parts of Italy, research projects in the field of autoimmune diseases, and especially in antiphospholipid syndrome. It is my passion; I've been developing it for several years, and I want to keep dedicating a part of my life to research.

8. What qualities do you think young scientists need?
I will start with it as it's the base for everything, passion. So, you have to be passionate about something. It's a long journey of research. Passion is fundamental. If you don't have passion, you will never dedicate the time that is needed to build up your research.

Second, you have to be consistent. You have to be consistent in your day by day, because otherwise your motivation will fade away, in the sense that you have to progress with your research, and the progress you make increases your motivation, and you only can progress if you are consistent.

You have to be resilient and adapt yourself to the conditions that you live in. You have to accept that sometimes you will have more time and sometimes you will have less time, and that maybe the results you are expecting from your research are not exactly as you planned them to be.

9. JCM is an open access (OA) journal. What is your opinion on the open access model of publishing?
With my group, we published some papers in the Journal of Clinical Medicine, and I have a positive idea of open access journals. It is important to give everyone the opportunity to read what's new, to read new research without having to have a subscription to a journal, and it opens up many opportunities. Obviously, you have to have financial support from your institution or external support to have the chance to publish in open access journals. There is always a balance between the two aspects, but I think it is wonderful that open access journals provide the opportunity for everyone to read about important advances in the medical field.

To learn more about the award process, please visit https://www.mdpi.com/journal/jcm/awards.

The Journal of Clinical Medicine (JCM, ISSN: 2077-0383) has been holding Editorial Board meetings since 2023. The Editorial Board meeting for the Section “Nuclear Medicine & Radiology” was hosted by Section Editor-in-Chief, Prof. Dr. Alberto Signore, and eleven Editorial Board Members were in attendance. We are extremely grateful for the strong support from our Editorial Board Members, and we sincerely hope that more Editorial Board Members will be able to participate in future meetings. We would like to invite everyone to review the content of this meeting.

The meeting started with a presentation about the development of the journal, with a particular focus on the Section “Nuclear Medicine & Radiology”. The following topics were discussed:

• The journal’s history, open access policy, and author benefits;
• Journal publication statistics and analysis of authors’ demographics (2018–2023);
• Journal awards, journal marketing activities, and journal social media promotion;
• Section EBM overview, decision-making statistics, and Section development statistics.

The following topics were covered in the discussion at this Editorial Board meeting:

The meeting mainly revolved around the self-construction and optimization of the Section. It is essential to comprehensively assess its overlapping scope with other journals and formulate a targeted adjustment plan to precisely define the Section's positioning. Promoting monthly highly cited papers and establishing a reward mechanism to attract more high-quality submissions was proposed. In addition, it was recommended to comb through and optimize the distribution of research fields within the Section according to the professional expertise of members, while at the same time actively exploring cutting-edge emerging research directions such as the application of artificial intelligence in radiology into the Section's scope, achieving in-depth expansion and enrichment of content and laying a solid foundation for the section's development.

Simultaneously, the Section should actively strive to expand the team by inviting radiology experts to the Editorial Board. Members should hold regular online meetings (annually) to gather collective wisdom and provide innovative insights and practical strategies for the Section's development. In-depth cooperation and exchanges with relevant international societies should be strengthened to promote the journal's development.

Attendee list (in no particular order):

• Prof. Dr. Alberto Signore (Section Editor-in-Chief), Department of Surgical-Medical Sciences and Translational Medicine, University of Rome Sapienza, Rome, Italy;
• Prof. Dr. Indra J. Das, Department of Radiation Oncology, Northwestern Memorial Hospital, Northwest University Feinberg School of Medicine, Chicago, USA;
• Prof. Dr. Felix M. Mottaghy, ^1. Director, Department of Nuclear Medicine, University Hospital, RWTH University Aachen, Aachen, Germany. ^2. Department of Radiology and Nuclear Medicine, Maastricht University Medical Center (MUMC+), AZ Maastricht, the Netherlands;
• Prof. Dr. Rémy Guillevin, ^1. Department of Imaging, University Hospital Center of Poitiers, Poitiers, France. ². Labcom I3M, University of Poitiers, Poitiers, France;
• Prof. Dr. Olivier Gheysens, Department of Nuclear Medicine, Cliniques Universitaires Saint-Luc and Institute of Clinical and Experimental Research (IREC), Université Catholique de Louvain (UCLouvain), Brussels, Belgium;
• Prof. Dr. Adriaan A. Lammertsma, Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands;
• Dr. David Ulmert, Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA;
• Prof. Dr. Enrico G. Caiani, Dipartimento di Elettronica, Informazione e Bioingegneria, Politecnico di Milano, Milan, Italy;
• Prof. Dr. Thomas Vogl, Clinic for Radiology and Nuclear Medicine, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany;
• Prof. Dr. Martin R. Prince, ^1. Department of Radiology, Weill Cornell Medicine, New York, USA. ^2. Columbia College of Physicians and Surgeons, New York, USA;
• Dr. Carlo Cavaliere, IRCCS Synlab SDN, Naples, Italy;
• Dr. Mario Ganau, Department of Neurosurgery, Oxford University Hospitals NHS Foundation, Oxford, UK.

The latest official CiteScore (2023 Scopus data) for the Journal of Clinical Medicine is 5.7, ranking 80/636 (Q1) in the “General Medicine” category. The current impact factor of JCM is 3.0 (2023), ranking 59/329 (Q1) in the “Medicine, General & Internal” category.

To access more journal statistics, please click here.

To access more information about the Section, please visit the following link: https://www.mdpi.com/journal/jcm/sections/Nuclear_Medicine_Radiology.

JCM Editorial Office

Welcome from the Chair:
We would like to invite you to an engaging webinar focusing on the latest advancements in diabetic foot care. This event will bring together leading experts to explore innovative approaches and technologies that are transforming the way we manage diabetic foot complications.

This webinar will cover a wide range of topics, including cutting-edge research in diabetic foot management, technological innovations in offloading solutions, and strategies for preventing complications. Emphasis will particularly be given to the management of Charcot foot, an often challenging condition, and the latest breakthroughs in cellular therapies for patients who have no revascularization options.

This is a unique opportunity to deepen your understanding of the current trends and gain practical insights into improving patient outcomes. Whether you are a clinician, researcher, or healthcare professional, this webinar will provide crucial knowledge to enhance your practice and drive better results in diabetic foot care.

Do not miss the chance to be part of this experience. Together, we can take strides towards revolutionizing care for patients with diabetic foot conditions.

Date: 20 December 2024
Time: 3:00 to 5:00 PM (CET)
Webinar ID: 835 7347 2310
Webinar Secretariat: journal.webinar@mdpi.com

Register now for free!

Program

Registration:
This is a free webinar. After registering, you will receive a confirmation email containing information on how to join.

Registrations with academic institutional email addresses will be prioritized. Certificates of attendance will be delivered to those who attend the live webinar.

If you are unable to attend, register anyway and we will let you know when the recording is available to watch.

Webinar Chairs and Speakers:

• Prof. Dr. José Luis Lázaro Martínez, Diabetic Foot Unit, Universidad Complutense de Madrid, Madrid, Spain;
• Prof. Dr. Luigi Uccioli, Diabetic Foot Unit, Department Systems Medicine, University of Rome Tor Vergata, Rome, Italy;
• Prof. Dr. Sicco A Bus, Department of Rehabilitation Medicine, Amsterdam University Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands, and Program Rehabilitation & Development, Amsterdam Movement Sciences Research Institute, van der Boechorststraat 9, 1081 BT Amsterdam, the Netherlands;
• Dr. Venu Kavarthapu, Department of Orthopedic Surgery, King’s College NHS Foundation Trust, London SE5 9RS, UK;
• Dr. Marco Meloni, Section of Endocrinology and Metabolic Diseases, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy, and Division of Endocrinology and Diabetology, Department of Medical Sciences, Fondazione Policlinico Tor Vergata, 00133 Rome, Italy;
• Dr. David G. Armstrong, Keck School of Medicine, University of Southern California, Los Angeles, CA, 90033, USA. 

Relevant Special Issue:
“Diabetic Foot Complications: Current Challenges and Future Prospects—3rd Edition”
Guest Editors: Prof. Dr. Luigi Uccioli and Prof. Dr. Jose Luis Lázaro-Martínez
Deadline for manuscript submission: 15 April 2025

For more information about the webinar, please visit the following website: https://sciforum.net/event/JCM-12.